EBS
Emergent BioSolutions Inc.
Key Financials
Operating Income
$100.1M
↑ 192.1%
Gross Profit
$317.6M
↓ 17.7%
Net Income
$52.6M
↑ 127.6%
Revenue
$742.9M
↓ 28.8%
Total Assets
$1.3B
↓ 5.1%
Total Liabilities
$796.0M
↓ 12.2%
Shareholders' Equity
$522.6M
↑ 8.2%
EPS (Diluted)
$0.93
↑ 125.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EBS |
| Company Name | Emergent BioSolutions Inc. |
| CIK | 1367644 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-631-3200 |